PBGENE-HBV Eliminates cccDNA Evidence in 92% of Evaluable Hep B Patients, Phase 2 Set for Q1 2027
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision's PBGENE-HBV delivered undetectable pgRNA in 11 of 12 evaluable chronic hepatitis B patients (92%), including all six at the 0.4 mg/kg go-forward dose, with paired liver biopsies showing roughly 1-log and 1.5-log cccDNA reductions. The first HBeAg-positive patient — a population with far higher liver cccDNA and viral load — cleared pgRNA after the second 0.4 mg/kg dose, and all patients with at least six months of follow-up stayed undetectable, with the longest now approaching one year. Safety held up across 59 administrations in 25 patients with no dose-limiting toxicities and no serious adverse events at 0.4 mg/kg. The company picked 0.4 mg/kg for a global Phase 2 ELIMINATE-B2 study testing monotherapy and an ASO combination, with dosing expected in Q1 2027 and initial open-label data in H2 2027. This lands two days after the Q3 report showing a narrowed $7.6M net loss and $108.0M of cash with runway through 2028, so the balance sheet supports the Phase 2 spend. The full data set is presented Sunday, November 8, with an investor call Monday, November 9 at 8:00 AM ET.
At the time of this announcement, DTIL was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.